Eye-Opening Phase III Data For AbbVie’s HCV Combo Suggest A Tightened Race
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AbbVie anticipates filing its oral three-drug combination for hepatitis C early in the second quarter after unveiling impressive top-line Phase III data. The Abbott Laboratories spinout said its late-stage pipeline positions the company for strong growth starting in 2015.